Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow

Beam Therapeutics presented Phase I/II topline data for BEAM-302, its base-editing therapy targeting alpha-1 antitrypsin deficiency (AATD), a genetic liver and lung disorder. The trial assessed safety, tolerability, and efficacy in AATD patients, with preliminary results suggesting successful in vivo gene editing via lipid nanoparticle delivery. Early data showed sustained alpha-1 antitrypsin (AAT) protein level increases, a key biomarker for therapeutic potential, though full efficacy outcomes remain under evaluation. No serious adverse events were reported, supporting the therapy’s safety profile, but long-term effects require further monitoring in expanded trials. The results mark a milestone for Beam’s precision base-editing platform, positioning BEAM-302 as a potential first-in-class treatment for AATD.